Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25834802 | 0.97 | ATM (0.45) | ATMSMN1; SMN2GAATP53MAPT | |
| SCHEMBL25834864 | 0.96 | TP53 (0.42) | ATMGAATP53MAPTTSHR | |
| SCHEMBL26034354 | 0.82 | ATM (0.43) | ATMSMN1; SMN2GAAMAPTTSHR | |
| SCHEMBL25834954 | 0.82 | ATM (0.43) | ATMSMN1; SMN2GAAMAPTTSHR | |
| SCHEMBL25836944 | 0.80 | TP53 (0.49) | SMN1; SMN2TP53MAPTTSHRKMT2A | |
| SCHEMBL25834990 | 0.80 | ATM (0.41) | ATMSMN1; SMN2GAATP53MAPT | |
| SCHEMBL24340634 | 0.78 | HPGD (0.48) | SMN1; SMN2GAATP53MAPTTSHR | |
| SCHEMBL25837025 | 0.78 | TP53 (0.51) | SMN1; SMN2TP53MAPTTSHRALOX15 | |
| SCHEMBL26032106 | 0.78 | CNR2 (0.40) | TP53MAPTTSHRALOX15RXFP1 | |
| SCHEMBL25851756 | 0.77 | TP53 (0.50) | SMN1; SMN2TP53MAPTTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | ATM 2852/4885SMN1; SMN2 155/4885GAA 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.